Day: April 15, 2026
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to